Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine Ophthalmic Gel for Moderate to Severe Dry Eye Disease
NCT06766357Phase 3Recruiting
- Sponsor
- Zhaoke Ophthalmology
- Start
- Apr 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cyclosporine 2% ophthalmic solution in dry eye disease (DED), sponsored by Zhaoke Ophthalmology. Primary endpoint: Eye Dryness Score at 84 days. Started Apr 2025; status: recruiting.
02
Drugs
cyclosporine 2% ophthalmic solution
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06766357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06766357.